Compare Newmont Corporation (NEM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Zoetis Inc — how do they compare? Newmont Corporation trades at $128.43 (market cap $133.91B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Newmont Corporation is far larger — about 4.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| NEM | ZTS | |
|---|---|---|
Market Cap | $133.91B | $30.40B |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $150.61 |
52-Week Low | $78.32 | $71.91 |
Enterprise Value | $130.50B | $37.96B |
Dividend Yield | 0.82% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $127.09, down 0.78% on the day, with strong fundamental performance including a 31.25% net income margin in 2025 and consistent earnings beats. The stock shows bullish technical signals with moving averages supporting upside, while recent news highlights production challenges and institutional accumulation. Revenue growth is robust, projected to reach $25.8 billion in 2026.
Outlook remains positive due to high analyst buy ratings (75.68%) and a $133.29 consensus price target, though risks include operational pressures and gold price volatility. The company's liquidity and debt reduction support shareholder returns, including dividends.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
